Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury

American Journal of Transplantation

Volumn 10, Issue 12, 2010, Pages 2586-2595

  Crikis, S ^a   Lu, B ^a   Murray Segal, L M ^a   Selan, C ^a   Robson, S C ^b   D'Apice, A J F ^a   Nandurkar, H H ^a   Cowan, P J ^a   Dwyer, K M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenosine; cold ischemia; organ protection and preservation; renal ischemia reperfusion injury; transgenic; transplant; warm ischemia

Indexed keywords

(3 CHLOROSTYRYL)CAFFEINE; ADENOSINE; ADENOSINE A2A RECEPTOR ANTAGONIST; CD39 ANTIGEN; CREATININE; UNCLASSIFIED DRUG; UREA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; COLD ISCHEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYOPRESERVATION; GRAFT RECIPIENT; HISTOLOGY; ISCHEMIA; KIDNEY GRAFT; KIDNEY ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UREA BLOOD LEVEL; VASCULARIZATION; WILD TYPE;

ADENOSINE; ANIMALS; ANTIGENS, CD; APYRASE; COLD ISCHEMIA; HUMANS; KIDNEY CORTEX NECROSIS; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; REPERFUSION INJURY;

EID: 78649867585     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03257.x     Document Type: Article

References (45)

1. Foley DP, Fernandez LA, Leverson G, et al,. Donation after cardiac death: The University of Wisconsin experience with liver transplantation. Ann Surg 2005; 242: 724-731.
2. Stubenitsky BM, Brasile L, Booster MH, Haisch CE, Kootstra G,. Deletrious effect of prolonged cold ischemia on renal function. Transpl Int 2001; 14: 256-260.
3. Halloran P, Aprile M,. Factors influencing early renal function in cadaver kidney transplants. A case-control study. Transplantation 1988; 45: 122-127.
4. Southard JH, Van Gulik TM, Ametani MS, et al,. Important components of the UW solution. Transplantation 1990; 49: 251-257.
5. Linden J,. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-787.
6. Linden J,. New insights into the regulation of inflammation by adenosine. J Clin Invest 2006; 116: 1835-1837.
7. Joshi S, Hartl R, Wang M, et al,. The acute cerebrovascular effects of intracarotid adenosine in nonhuman primates. Anesth Analg 2003; 97: 231-237, table of contents.
8. Day YJ, Li Y, Rieger JM, Ramos SI, Okusa MD, Linden J,. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol 2005; 174: 5040-5046.
9. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J,. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006; 203: 2639-2648.
10. Lee HT, Gallos G, Nasr SH, Emala CW,. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 2004; 15: 102-111.
11. Ely SW, Berne RM,. Protective effects of adenosine in myocardial ischemia. Circulation 1992; 85: 893-904.
12. Ely SW, Mentzer RM, Jr, Lasley RD, Lee BK, Berne RM,. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 1985; 90: 549-556.
13. Grenz A, Zhang H, Eckle T, et al,. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 2007; 18: 833-845.
14. Grenz A, Zhang H, Hermes M, et al,. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007; 21: 2863-2873.
15. Eltzschig HK, Ibla JC, Furuta GT, et al,. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198: 783-796.
16. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP,. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009; 113: 224-232.
17. Hart ML, Gorzolla IC, Schittenhelm J, Robson SC, Eltzschig HK,. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol 2010; 184: 4017-4024.
18. Dwyer KM, Robson SC, Nandurkar HH, et al,. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113: 1440-1446.
19. Enjyoji K, Sevigny J, Lin Y, et al,. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999; 5: 1010-1017.
20. Jacobson KA, Nikodijevic O, Padgett WL, Gallo-Rodriguez C, Maillard M, Daly JW,. 8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett 1993; 323: 141-144.
21. Lee HT, Xu H, Nasr SH, Schnermann J, Emala CW,. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol 2004; 286: F298-F306.
22. Robson S,. The therapeutic potential of CD39: Interview with Dr Simon Robson by Emma Quigley. Expert Opin Ther Targets 2006; 10: 649-652.
23. Gobe G, Willgoss D, Hogg N, Schoch E, Endre Z,. Cell survival or death in renal tubular epithelium after ischemia-reperfusion injury. Kidney Int 1999; 56: 1299-1304.
24. Daemen MA, Van't Veer C, Denecker G, et al,. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104: 541-549.
25. Bilbao G, Contreras JL, Eckhoff DE, et al,. Reduction of ischemia-reperfusion injury of the liver by in vivo adenovirus-mediated gene transfer of the antiapoptotic Bcl-2 gene. Ann Surg 1999; 230: 185-193.
26. Chalasani G, Li Q, Konieczny BT, et al,. The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. J Immunol 2004; 172: 7813-7820.
27. Friedewald JJ, Rabb H,. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486-491.
28. Lai LW, Yong KC, Igarashi S, Lien YH,. A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney Int 2007; 71: 1223-1231.
29. Burne MJ, Daniels F, El Ghandour A, et al,. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001; 108: 1283-1290.
30. Koning OH, Ploeg RJ, Van Bockel JH, et al,. Risk factors for delayed graft function in cadaveric kidney transplantation: A prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation 1997; 63: 1620-1628.
31. Connolly JK, Dyer PA, Martin S, Parrott NR, Pearson RC, Johnson RW,. Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation 1996; 61: 709-714.
32. Zheng LM, Zychlinsky A, Liu CC, Ojcius DM, Young JD,. Extracellular ATP as a trigger for apoptosis or programmed cell death. J Cell Biol 1991; 112: 279-288.
33. Lu B, Rajakumar SV, Robson SC, et al,. The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation 2008; 86: 1707-1712.
34. Yang Z, Day YJ, Toufektsian MC, et al,. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005; 111: 2190-2197.
35. Eltzschig HK, Abdulla P, Hoffman E, et al,. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 2005; 202: 1493-1505.
36. Grenz A, Osswald H, Eckle T, et al,. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 2008; 5: e137.
37. Rabb H, O'Meara YM, Maderna P, Coleman P, Brady HR,. Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997; 51: 1463-1468.
38. Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD,. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 2010; 77: 771-780.
39. Ascon M, Ascon DB, Liu M, et al,. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009; 75: 526-535.
40. Pommey S, Lu B, Robson S, D'Apice A, Cowan P, Dwyer K,. Donor livers expressing human CD39 are less susceptible to ischemia reperfusion injury in a mouse liver transplant model. Xenotransplantation 2009; 16: 8 -.
41. Rosenberger P, Schwab JM, Mirakaj V, et al,. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 2009; 10: 195-202.
42. Deaglio S, Dwyer KM, Gao W, et al,. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
43. Hansen TN, Haworth RA, Southard JH,. Warm and cold ischemia result in different mechanisms of injury to the coronary vasculature during reperfusion of rat hearts. Transplant Proc 2000; 32: 15-18.
44. Mason J, Torhorst J, Welsch J,. Role of the medullary perfusion defect in the pathogenesis of ischemic renal failure. Kidney Int 1984; 26: 283-293.
45. Dezfouli S, Crikis S, Dwyer K, et al,. Development of RSOLCD39-PSGL as a novel therapeutic with anti-thrombotic and enti-inflammatory effects. XXII ISTH Congress 2009; Thursday July 16 2009; Boston USA, 2009.